References
- Cash J D., Gadev A MA, de Costa J. Release of plasminogen activator and factor VIII in response to LVP, AVP, DDAVP, angiotensin II and oxytocin in man. Br J Haemotol 1974; 27: 363–4
- Yamada S, Yamada R, Ishii A, et al. Activity of tissue plasminogen activator in various disorders. J Med Pharmacol Science 1989; 21: 655–7
- Hersch L S., Kunelis T, Francis R B. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987; 69: 1315–9
- Juhan-Vague I, Valadier J, Alessi M C., et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67–72
- Gram J, Jespersen J. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterizes a risk group among survivors of acute myocardial infarction. Thromb Haemost 1987; 57: 137–9
- Watanabe S, Sasamata M, Katoh M, et al. t-PA activity assay method in blood sample using dipstick coated with a monoclonal antibody SP-322. Thromb Haemost 1989; 62: 95
- Sekimoto H. β-Lipoprotein. Japanese J Clin Chem 1971; 1: 64–9
- Oseroff A, Krishnamurti C, Hassett A, et al. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88–92
- Hamsten A, Faire U, Walldius G. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; iiii: 3–8